AddLife presentation Kristina Willgrd - CEO ADDLIFE AB OPERATIONS - - PowerPoint PPT Presentation

ADDLIFE AB OPERATIONS INVESTORS

AddLife presentation Kristina Willgård - CEO

ADDLIFE AB OPERATIONS INVESTORS

• A leading independent player in the Nordic

Life Science market

• Provide equipment, consumables and related

services mainly to the healthcare sector in the Nordics

• Company heritage dates back to 1906
• Listed on Stockholm Stock Exchange 2016
• 29 subsidiaries
• Two business areas; Labtech and Medtech
• Net sales R12M Q3 2018

AddLife in brief

245 EURm

32

2017

2

500 1000 1500 2000 2500 3000 2004 2013-14 2014-15 2015-16 2016 2017 Q3 2018

ADDLIFE AB OPERATIONS INVESTORS

Geographical markets

32

Population Nordics

ADDLIFE AB OPERATIONS INVESTORS

Demographics Structural Changes Technology Public Procurement

Market Trends

ADDLIFE AB OPERATIONS INVESTORS

Our Market

Labtech Medtech

Healthcare & Home care R&D Diagnostics Industrial analysis

Labtech

Net sales: 145 EURm EBITA: 17 EURm Subsidiaries: 17 Employees: 365

ADDLIFE AB OPERATIONS INVESTORS LABTECH MEDTECH

Medtech

Net sales: 100 EURm EBITA: 9 EURm Subsidiaries: 13 Employees: 225

ADDLIFE AB OPERATIONS INVESTORS

Combine the small company’s… With the large company’s…

Flexibility Personality Effectiveness Resources Network Sustainability

”Small scale business – large scale wise”

Decentralized organization with entrepreneurial business acumen

AddLife Academy 750

• AddLife Vision and Corporate Philsophy
• Sales and Business
• Service delivery
• Leadership
• Marketing & Finance

ADDLIFE AB OPERATIONS INVESTORS

Financial goals

Profit growth

Long term 15 percent yearly

Profitability

> 45 percent EBITA/WC

Dividend

30-50 percent of profit after tax

ADDLIFE AB OPERATIONS INVESTORS

Q3 2018

Figures and facts

ADDLIFE AB OPERATIONS INVESTORS

Q3 ”Continued growth”

Q3

• Net Sales

SEK 578m (517), +12%, organic 4%

• EBITA

SEK 51m (44) +16%

• EBITA-margin

8.8% (8.5)

R12 Months

• Net Sales

SEK 2,465 (2,276) +8%

• EBITA

SEK 250 (231) +8%

• EBITA-margin

10.1% (10.1)

7

ADDLIFE AB OPERATIONS INVESTORS

Balance sheet

12

ADDLIFE AB OPERATIONS INVESTORS

Our strategies

1

Market leading positions

2

Operating mobility

3

Acquisitions

Aquisitions

• Profitable companies with

positive development

• New markets, segments,

solutions or services

• Complement to existing offer
• Trading companies and

companies with nisched own branded products

• Strong management

ADDLIFE AB OPERATIONS INVESTORS

• A step beyond the Nordic region
• Great business-related similarities
• 60% Labtech and 40% is Medtech
• Company heritage dates back to 1978
• HQ in Vienna, Austria
• 12 subsidiaries in the CEE region
• Net sales 2017/2018

Yesterday we announced the acquisition of Biomedica

64 EURm 32

2017

2

0,5 5 25 43 64 10 20 30 40 50 60 70 1978 1988 1998 2008 2018

ADDLIFE AB OPERATIONS INVESTORS

A game changer!

134

Population CEE

32

Population Nordics

Net sales approx 3,115 MSEK with EBITA approx 294 MSEK

ADDLIFE AB OPERATIONS INVESTORS

New share issues

• Issue in kind of 100 MSEK to the sellers of

Biomedica

• Preferential rights issue for AddLife´s existing

shareholders of 500 MSEK

The purpose of the rights issue is to raise capital to

continue to pursue AddLife’s growth strategy and to carry out more strategic acquisitions.

ADDLIFE AB OPERATIONS INVESTORS

Share development since listing

ADDLIFE AB OPERATIONS INVESTORS

Q & A